PDGF receptors as cancer drug targets

被引：369

作者：

Pietras, K

Sjöblom, T

Rubin, K

Heldin, CH

Östman, A

机构：

[1] Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden

[2] Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden

来源：

CANCER CELL | 2003年 / 3卷 / 05期

关键词：

D O I：

10.1016/S1535-6108(03)00089-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：439 / 443

页数：5

共 49 条

[1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[2] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[3] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[4] Developmental roles of platelet-derived growth factors [J].

Betsholtz, C ;

Karlsson, L ;

Lindahl, P .

BIOESSAYS, 2001, 23 (06) :494-507

[5]

Buchdunger E, 1996, CANCER RES, V56, P100

[6] Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors [J].

Cao, RH ;

Bråkenhielm, E ;

Li, XR ;

Pietras, K ;

Widenfalk, J ;

Östman, A ;

Eriksson, U ;

Cao, YH .

FASEB JOURNAL, 2002, 16 (12) :1575-1583

[7] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[8] Human brain tumor-derived PDGFR-α deletion mutant is transforming [J].

Clarke, ID ;

Dirks, PB .

ONCOGENE, 2003, 22 (05) :722-733

[9] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[10] MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis [J].

Coussens, LM ;

Tinkle, CL ;

Hanahan, D ;

Werb, Z .

CELL, 2000, 103 (03) :481-490

← 1 2 3 4 5 →